Stock 2157 LEPU BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Lepu Biopharma Co., Ltd.

Equities

2157

CNE100004SM4

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:03 2024-05-23 am EDT 		5-day change 1st Jan Change
4.92 HKD -2.19% Intraday chart for Lepu Biopharma Co., Ltd. -13.53% +16.86%
May. 17 Lepu Biopharma Targets Up to HK$230 MIllion in Share Placement; Shares Fall 5% MT
Apr. 12 Keymed Biosciences Advances Solid Tumors Drug With First Patient Study MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
LEPU BIOPHARMA CO., LTD. Stock Lepu Biopharma Co., Ltd.
+16.86% 1.07B -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.18% 115B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.57% 106B
B+
BIONTECH SE Stock BioNTech SE
-4.19% 24.69B
B+
ARGENX SE Stock argenx SE
-2.33% 21.97B
B
GENMAB A/S Stock Genmab A/S
-6.03% 19.27B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.13% 17.56B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.50% 17.32B
A-
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.67% 14.03B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.13% 12.13B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2157 Stock
  4. Ratings Lepu Biopharma Co., Ltd.